Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis
<h3>Objective</h3><p dir="ltr">The main aim is to compare the risk of severe hypoglycemia associated with the modified-release (MR) gliclazide against glimepiride in diabetic older adults. </p><h3>Methods</h3><p dir="ltr">All older adult...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513548764315648 |
|---|---|
| author | Ahmed Fouad Algendy (18102706) |
| author2 | Ben Illigens (846757) Ameena Alyazeedi (18102703) |
| author2_role | author author |
| author_facet | Ahmed Fouad Algendy (18102706) Ben Illigens (846757) Ameena Alyazeedi (18102703) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ahmed Fouad Algendy (18102706) Ben Illigens (846757) Ameena Alyazeedi (18102703) |
| dc.date.none.fl_str_mv | 2022-05-19T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.2147/dmso.s339331 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Increased_Frequency_of_Severe_Hypoglycemia_with_the_Modified-Release_Gliclazide_Compared_to_Glimepiride_in_Diabetic_Older_Adults_Propensity_Score-Adjusted_Analysis/29022713 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences sulfonylurea diabetes cardiovascular falls fractures |
| dc.title.none.fl_str_mv | Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Objective</h3><p dir="ltr">The main aim is to compare the risk of severe hypoglycemia associated with the modified-release (MR) gliclazide against glimepiride in diabetic older adults. </p><h3>Methods</h3><p dir="ltr">All older adult diabetic patients who attended the emergency department (ED) between the 1st of Aug. 2017 and the end of Mar 2020 on gliclazide MR or glimepiride are included in two cohorts. We compared baseline differences between cohorts in demographics, lab results, diabetes complications, comorbidities, and drugs using the chi-squared test for categorical variables and unpaired t-test for continuous variables. All the baseline variables are used in a logistic regression to produce the propensity scores for receiving gliclazide MR. The primary outcome was Severe Hypoglycemia requiring Emergency Admission (SHEA). We used documented hypoglycemia, falls, fractures, Cardiovascular ED Admission (CVEA), and recurrent ED admissions as secondary outcomes. We used a univariate logistic regression followed by a propensity score-adjusted logistic regression to identify the adjusted odds ratio. We did a subgroup analysis for low and moderate-high doses users. </p><h3>Results</h3><p dir="ltr">We included 2320 patients, 1786 were on gliclazide MR while 534 were on glimepiride. The risk of SHEA (Adjusted Odds Ratio AOR 6.74, p=0.002), falls (AOR 1.43, p=0.003), fractures (AOR 1.43, p=0.01), CVEA (AOR 1.66, p< 0.001), recurrent ED admission (AOR 1.39, p=0.002) were significantly higher. At the same time, documented hypoglycemia was insignificantly higher (AOR 1.17, p= 0.444) with gliclazide MR compared to glimepiride. The low doses of both treatments did not show any SHEA cases, while the results with higher doses showed the same pattern of increased risk with gliclazide MR as the principle analysis. </p><h3>Conclusion</h3><p dir="ltr">Using gliclazide MR for older patients may not be a relatively safer alternative to avoid severe hypoglycemia and its possible consequences compared to glimepiride. It may be added to glimepiride in the Beers list of medications to be avoided in older adults.</p><h2>Other Information</h2><p dir="ltr">Published in: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.2147/dmso.s339331" target="_blank">https://dx.doi.org/10.2147/dmso.s339331</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_8b01e866d8a40167803aa0bb3fe099e8 |
| identifier_str_mv | 10.2147/dmso.s339331 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29022713 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted AnalysisAhmed Fouad Algendy (18102706)Ben Illigens (846757)Ameena Alyazeedi (18102703)Biomedical and clinical sciencesMedical biochemistry and metabolomicsPharmacology and pharmaceutical sciencessulfonylureadiabetescardiovascularfallsfractures<h3>Objective</h3><p dir="ltr">The main aim is to compare the risk of severe hypoglycemia associated with the modified-release (MR) gliclazide against glimepiride in diabetic older adults. </p><h3>Methods</h3><p dir="ltr">All older adult diabetic patients who attended the emergency department (ED) between the 1st of Aug. 2017 and the end of Mar 2020 on gliclazide MR or glimepiride are included in two cohorts. We compared baseline differences between cohorts in demographics, lab results, diabetes complications, comorbidities, and drugs using the chi-squared test for categorical variables and unpaired t-test for continuous variables. All the baseline variables are used in a logistic regression to produce the propensity scores for receiving gliclazide MR. The primary outcome was Severe Hypoglycemia requiring Emergency Admission (SHEA). We used documented hypoglycemia, falls, fractures, Cardiovascular ED Admission (CVEA), and recurrent ED admissions as secondary outcomes. We used a univariate logistic regression followed by a propensity score-adjusted logistic regression to identify the adjusted odds ratio. We did a subgroup analysis for low and moderate-high doses users. </p><h3>Results</h3><p dir="ltr">We included 2320 patients, 1786 were on gliclazide MR while 534 were on glimepiride. The risk of SHEA (Adjusted Odds Ratio AOR 6.74, p=0.002), falls (AOR 1.43, p=0.003), fractures (AOR 1.43, p=0.01), CVEA (AOR 1.66, p< 0.001), recurrent ED admission (AOR 1.39, p=0.002) were significantly higher. At the same time, documented hypoglycemia was insignificantly higher (AOR 1.17, p= 0.444) with gliclazide MR compared to glimepiride. The low doses of both treatments did not show any SHEA cases, while the results with higher doses showed the same pattern of increased risk with gliclazide MR as the principle analysis. </p><h3>Conclusion</h3><p dir="ltr">Using gliclazide MR for older patients may not be a relatively safer alternative to avoid severe hypoglycemia and its possible consequences compared to glimepiride. It may be added to glimepiride in the Beers list of medications to be avoided in older adults.</p><h2>Other Information</h2><p dir="ltr">Published in: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.2147/dmso.s339331" target="_blank">https://dx.doi.org/10.2147/dmso.s339331</a></p>2022-05-19T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.2147/dmso.s339331https://figshare.com/articles/journal_contribution/Increased_Frequency_of_Severe_Hypoglycemia_with_the_Modified-Release_Gliclazide_Compared_to_Glimepiride_in_Diabetic_Older_Adults_Propensity_Score-Adjusted_Analysis/29022713CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/290227132022-05-19T09:00:00Z |
| spellingShingle | Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis Ahmed Fouad Algendy (18102706) Biomedical and clinical sciences Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences sulfonylurea diabetes cardiovascular falls fractures |
| status_str | publishedVersion |
| title | Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis |
| title_full | Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis |
| title_fullStr | Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis |
| title_full_unstemmed | Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis |
| title_short | Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis |
| title_sort | Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis |
| topic | Biomedical and clinical sciences Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences sulfonylurea diabetes cardiovascular falls fractures |